Direct cost savings as well as indirect effects created by increased diagnostics accuracy.
The unique combination of molecular biology, robotics, NGS and AI provides market-leading accuracy.
Manual stages of work almost fully minimized, enabling unparallelled scalability and processing times.
The core of Geno1™ is its unique combination of molecular biology, robotics, next-generation DNA sequencing (NGS) and artificial intelligence (AI).
Geno1™ addresses the key shortcomings of other NGS-based liquid biopsy solutions through its minimalistic but powerful design, leading to substantially lower test costs, higher test accuracy and faster turn-around-time.
Geno1™ is a unique technology which enables cutting-edge medical technology that is genuinely accessible.
Our unique ligation-based molecular barcoding technology leverages the power of NGS platforms and AI. The laboratory design of Geno1™ has been guided by the principle of minimalism: reduce all processing steps to minimum and make them as simple as possible. Through these design choices, Geno1™ provides a lightweight but powerful molecular counting platform which scales to any number of oncologically relevant targets within any number of patient samples.
The focus can be outside oncology; Geno1™ can be applied to any NGS-based area.
We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1™ for out-licensing and are continuously looking for new long-term partnerships.
Join us in democratizing true game-changing technology!